A Patient-Directed Mobile Tool to Streamline the QoL Assessment and Monitoring in Urothelial Carcinoma

Launched by IRCCS SAN RAFFAELE · May 13, 2025

Keywords

ClinConnect Summary

This clinical trial is looking at how to create a helpful web app for patients with urothelial carcinoma, a type of bladder cancer. The main goal is to find out what information and tools patients would like to see in this app to help them better understand their condition and make informed decisions about their treatment. Participants in this study will be asked to fill out questionnaires about what features would be most beneficial for them as they manage their health and quality of life during treatment.

To be eligible to join the trial, participants must be at least 18 years old, have a confirmed diagnosis of urothelial carcinoma, and be receiving or about to start systemic treatments like chemotherapy or targeted therapy. They should also own a mobile device, be able to understand and speak Italian, and be willing to provide informed consent. By participating, individuals will have the chance to share their opinions on what would make this app useful, ultimately helping to create a tool that enhances the experience of others facing similar health challenges.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • histological diagnosis of urothelial carcinoma;
• • ≥ 18 years old,
• • candidate for systemic treatment with chemotherapy, immune-checkpoint inhibitors, antibody-drug conjugates, or target therapy (patients can be enrolled also if the treatment has started),
• • possession of a mobile device (e.g., smartphone or personal computer) with the physical and psychological ability to use mobile devices,
• • understanding and speaking the Italian language,
• • ability to sign an informed consent.
• Exclusion Criteria:
• • not possession of a mobile device,
• • unwillingness to give informed consent.